Leveraging Innate Immune and Metabolic Cell Death Pathways in Cancer Therapies
Cancer Communications · 01.01.2026 · 46
DOI: 10.34133/cancomm.0062 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Communications, online erschienen am 12.11.2026. Verfasst von Yaqiu Wang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA. Hauptthemen laut MEDLINE: Immunity, Innate, Neoplasms, Cell Death. Die Arbeit nennt 172 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCI NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Cancer cells evade cell death, and overcoming this resistance has been a fundamental challenge in cancer treatment. Innate immunity is critical in detecting cellular alterations, including those that accompany malignant transformation. Furthermore, innate immune signaling can activate tumor cell-intrinsic cell death pathways and immune-mediated killing to eliminate cancer cells. Several cell death pathways that are relevant to cancer have been defined, and we have broadly categorized these as caspase-dependent and caspase-independent pathways to reflect the key mechanistic difference between these groups for this discussion. The caspase-dependent pathways are genetically regulated by caspases; these include apoptosis, pyroptosis, and PANoptosis, which require caspases, and the contrasting pathway necroptosis, which is initiated in the absence of caspase-8. In contrast to caspase-dependent pathways, the caspase-independent pathways are driven by disruption of essential metabolic processes and include ferroptosis, disulfidptosis, cuproptosis, and mitoxyperilysis. Apoptosis is nonlytic, while all other pathways discussed here are lytic. Lytic cell death can involve the release of damage-associated molecular patterns (DAMPs) or cytokines that can further amplify innate immune cell death responses and paracrine PANoptosis, contributing to a sustained pro-inflammatory environment. Cancer cells vary widely in their expression of cell death mediators, leading to differing sensitivities to these cell death pathways. This heterogeneity represents both a therapeutic challenge and opportunity: inflammatory cell death within the tumor microenvironment is a double-edged sword, priming antitumor immunity in some contexts while fueling immunosuppression in others. In this review, we describe the cell death pathways relevant to cancer, highlighting recent advances in our mechanistic understanding of these pathways and discussing how this informs therapeutic targeting in cancers. Overall, a thorough understanding of innate immune responses in cancer cell death and the immunological consequences are essential to leverage these mechanisms to inform biomarker-guided patient stratification and develop next-generation cancer therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.
ORCID-Profile: Thirumala-Devi Kanneganti
Förderung
- NIAID NIH HHS
- NCI NIH HHS
- National Institute of Allergy and Infectious Diseases
- National Cancer Institute
- American Lebanese Syrian Associated Charities
Zitieren
APA
Wang, Y., & Kanneganti, T. D. (2026). Leveraging Innate Immune and Metabolic Cell Death Pathways in Cancer Therapies. Cancer Communications, 46. https://doi.org/10.34133/cancomm.0062
Vancouver
Wang Y, Kanneganti TD. Leveraging Innate Immune and Metabolic Cell Death Pathways in Cancer Therapies. Cancer Communications. 2026;46. doi:10.34133/cancomm.0062
BibTeX
@article{Wang2026,
author = {Wang, Yaqiu and Kanneganti, Thirumala-Devi},
title = {Leveraging Innate Immune and Metabolic Cell Death Pathways in Cancer Therapies},
journal = {Cancer Communications},
year = {2026},
volume = {46},
doi = {10.34133/cancomm.0062}
}
EUVIMED